Overweight

Metabolic·MeSH: Overweight

Prevalence

0.1 / 100K

49 drugs in development·19 companies·96 clinical trials

Drug Pipeline by Phase

Approved(4)

Phase 3(7)

Drug	Company
azd9550	ASTRAZENECA PLC (AZN)
cagrisema	Novo Nordisk A/S (NVO)
Eloralintide	ELI LILLY & Co (LLY)
MET097	PFIZER INC (PFE)
nnc0487-0111	Novo Nordisk A/S (NVO)
regn20934	REGENERON PHARMACEUTICALS, INC. (REGN)
UBT251	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(12)

Drug	Company
aleniglipron (GSBR-1290)	Structure Therapeutics Inc. (GPCR)
ALN-4324	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
AZD6234	ASTRAZENECA PLC (AZN)
enobosarm	VERU INC. (VERU)
Macupatide	ELI LILLY & Co (LLY)
met-097i	Metsera, Inc. (MTSR)
na-931	Q BioMed Inc. (QBIO)
na-931 150 mg + no tirzepatide	Q BioMed Inc. (QBIO)
nnc0662-0419	Novo Nordisk A/S (NVO)
olatorepatide	REGENERON PHARMACEUTICALS, INC. (REGN)
semaglutide weekly	VERU INC. (VERU)
ubt251	Novo Nordisk A/S (NVO)

Phase 1(18)

Drug	Company
cagrilintide	Novo Nordisk A/S (NVO)
Cagrilintide	ENANTA PHARMACEUTICALS INC (ENTA)
cagrilintide b	Novo Nordisk A/S (NVO)
cagrilintide d	Novo Nordisk A/S (NVO)
coc	AMGEN INC (AMGN)
glucose-dependent insulinotropic polypeptide	Novo Nordisk A/S (NVO)
ibio-600	iBio, Inc. (IBIO)
ibio-610	iBio, Inc. (IBIO)
LY4064912	ELI LILLY & Co (LLY)
ly4167586	ELI LILLY & Co (LLY)
maridebart cafraglutide	AMGEN INC (AMGN)
met-233i	Metsera, Inc. (MTSR)
nnc0487-0111 a	Novo Nordisk A/S (NVO)
nnc6989-0001 a	Novo Nordisk A/S (NVO)
oral contraceptive	Novo Nordisk A/S (NVO)
PF-08653944	PFIZER INC (PFE)
sar441255	Sanofi (SNY)
WVE-007	Crinetics Pharmaceuticals, Inc. (CRNX)

Preclinical(2)

Drug	Company
met-097o	Metsera, Inc. (MTSR)
met-224o	Metsera, Inc. (MTSR)

N/A(1)

Drug	Company
Incretin-Based Treatment	Merus N.V. (MRUS)

Phase 1/Phase 2(3)

Phase 4(2)

Drug	Company
azd6234 in combination with azd9550	ASTRAZENECA PLC (AZN)
plocebo	ASTRAZENECA PLC (AZN)

BioSniper tracks 49 drugs in development for Overweight across 19 companies.

There are 96 clinical trials targeting Overweight tracked by BioSniper.

The estimated prevalence of Overweight is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.